This bulletin discusses the evidence and place in therapy for rapid-acting and long acting insulin analogues in both type one and type two diabetes. Inhaled insulin is also covered briefly.
In addition to the Bulletin a range of educational support materials are also available including a quiz, case study and presentation slides. These materials deal with type one diabetes and type two diabetes as separate topic areas.
Action: Clinicians who initiate or manage insulin therapy for patients with diabetes will find the Bulletin is a useful summary of the current evidence. The educational materials will be useful to anyone wishing to test their own understanding or to cascade this information on to other clinicians.
|« ABPI threatens generic switch court action||Which aspirin dose? »|